Accuracy evaluation of a 3D ultrasound-guided biopsy system - Abstract

Early detection of prostate cancer is critical in maximizing the probability of successful treatment. Current systematic biopsy approach takes 12 or more randomly distributed core tissue samples within the prostate and can have a high potential, especially with early disease, for a false negative diagnosis. The purpose of this study is to determine the accuracy of a 3D ultrasound-guided biopsy system. Testing was conducted on prostate phantoms created from an agar mixture which had embedded markers. The phantoms were scanned and the 3D ultrasound system was used to direct the biopsy. Each phantom was analyzed with a CT scan to obtain needle deflection measurements. The deflection experienced throughout the biopsy process was dependent on the depth of the biopsy target. The results for markers at a depth of less than 20 mm, 20-30 mm, and greater than 30 mm were 3.3 mm, 4.7 mm, and 6.2 mm, respectively. This measurement encapsulates the entire biopsy process, from the scanning of the phantom to the firing of the biopsy needle. Increased depth of the biopsy target caused a greater deflection from the intended path in most cases which was due to an angular incidence of the biopsy needle. Although some deflection was present, this system exhibits a clear advantage in the targeted biopsy of prostate cancer and has the potential to reduce the number of false negative biopsies for large lesions.

Written by:
Wooten WJ 3rd1, Nye JA1, Schuster DM1, Nieh PT2, Master VA2, Votaw JR1, Fei B3   Are you the author?
1Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA. 2Department of Urology, Emory University School of Medicine, Atlanta, GA. 3Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA ; Department of Biomedical Engineering, Emory University and Georgia Institute of Technology ; Department of Mathematics and Computer Science, Emory University, Atlanta, GA.

Reference: Proc SPIE. 2013 Mar 14;8671
doi: 10.1117/12.2007695


PubMed Abstract
PMID: 24392206

UroToday.com Prostate Cancer Section